What Lac-Hydrin Treats: Main Uses and Benefits

---

The topical prescription-strength formulation is commonly used in situations involving certain distressing symptoms of chronic dry skin disorders. It is used for managing xerosis (severe dry, scaly skin) and ichthyosis vulgaris (an inherited dry skin condition). This formulation is generally used across conditions characterized by periods of heightened symptoms of dryness. It provides support that helps ease the overall symptom burden for patients managing these long-term dermatological issues.

Targeted Symptom Management

This treatment plays a role in managing the symptom clusters that may become intense or disruptive, specifically targeting symptoms related to physical discomfort, such as skin roughness, excessive scaling, and the associated pruritus (itching). The key therapeutic benefit contributes to maintaining a softer, smoother skin texture. In situations where patients experience severe dryness, the treatment offers symptomatic relief that may assist with helping patients cope more steadily with symptom fluctuations, particularly when symptoms interfere with routine activities.

Quick Fact: Relief for Scaling and Roughness

The medication is relevant for easing symptoms that interfere with daily comfort, applied in addressing significant scaling and skin texture impairment to support general well-being during symptomatic periods.

Regulatory References

1. DailyMed official drug labeling for Ammonium Lactate

Who Can and Cannot Use Lac-Hydrin? — Official Regulatory Information

The eligibility for Lac-Hydrin (Ammonium Lactate 12% Cream and Lotion) is strictly defined by government regulatory documents, focusing on patient populations and absolute prohibitions. Use of the medicine is contraindicated in patients with a history of hypersensitivity to any ingredient in the formulation.

---

Age-Group Eligibility Rules

Age Group	Eligibility Status (as per FDA Labeling)
Infants and Children (Lotion)	Safety and effectiveness have been demonstrated.
Pediatric Patients (Cream)	Safety and effectiveness have been established in patients as young as 2 years old.
Geriatric Use (Age 65+)	Data is insufficient to determine if they respond differently; cautious dose selection is advised.

---

Conditional Use in Special Populations

For specific patient groups, use is restricted or conditional:

• Pregnancy: The medicine is classified as Pregnancy Category B and is permitted for use only if clearly needed.
• Lactation: Caution must be exercised when administered to a nursing woman.

There are no specific restrictions listed in the official labeling related to hepatic or renal impairment. This information defines who is officially allowed to receive the prescription product and under what conditions.

Interactions with other medicines and products

Interaction patterns for topical ammonium lactate (Lac-Hydrin) are officially defined by its highly localized effect and minimal systemic absorption, according to government regulatory information.

---

Topical-Topical Pharmacodynamic Interactions

The most relevant official interaction is a pharmacodynamic effect restricted to the site of application. Co-administration with other topical products that cause significant skin irritation, peeling, or dryness may lead to an additive effect. Regulatory documentation advises against the simultaneous use of such preparations to prevent the exacerbation of local adverse skin reactions. This restriction is consistent with the product’s function as an Alpha-Hydroxy Acid (AHA) derivative.

---

Absence of Documented Systemic Interactions

Official government labeling for ammonium lactate topical formulation confirms a lack of clinically significant systemic interactions.

Interaction Type	Status in Regulatory Documents
Systemic Contraindications	None documented for co-administration.
Metabolic (CYP) Interactions	None documented as clinically relevant.
Drug Transporter Interactions	None documented (e.g., P-gp, OATP).
Food, Alcohol, Supplements	No specific interaction patterns or restrictions documented.
Timing-Separation Rules	None mandated for systemic medicines.

The regulatory profile is characterized by the absence of constraints related to oral or injectable medicines, emphasizing that interaction concerns are restricted to the local application site.

The mechanism of action of ammonium lactate is defined by a unique dual-modality action focused entirely on influencing the structure and water content of the stratum corneum, the outermost layer of the epidermis. This dual role—a humectant and a mild keratolytic—is achieved through a pH-optimized formulation that supports both effects.

Modulating Epidermal Water Homeostasis

The primary mechanism centers on the lactate ion acting as a high-affinity humectant, a molecule that actively draws and binds water. This molecule penetrates the stratum corneum, directly augmenting the water content within the tissue and restoring the pool of Natural Moisturizing Factors (NMF). This molecular binding alters the physiological state of the epidermis, increasing its turgor and plasticity.

Enhancing the Natural Desquamation Pathway

The secondary, complementary effect is due to the alpha-hydroxy acid (AHA) component's ability to modulate corneocyte cohesion. It acts as a mild keratolytic agent, interfering with the adhesive bonds that tightly hold excess, hardened dead cells together. By weakening these bonds, the drug accelerates the natural desquamation process, facilitating the separation of redundant cellular material. The resulting physiological effect is the modulation of hyperkeratosis and structural changes to the tissue surface.

Official Administration Guidelines for Lac-Hydrin

Lac-Hydrin (ammonium lactate 12%) is a specialized, prescription-only pharmaceutical product designated exclusively for the topical route of administration. The medicine is supplied as a 12% lotion or cream, and its usage pattern is standardized for managing approved chronic dermatological conditions.

The standard labeled regimen involves applying the formulation to the affected areas of the skin. It is essential that the product be rubbed in thoroughly upon application. This procedure is generally performed twice daily, a frequency established to ensure consistent dermal exposure to the active ingredient. For proper administration, a specific preparation step is required for the lotion form: the container must be shaken well immediately prior to each use.

Regarding age groups, the safety and effectiveness of the medication have been demonstrated for use in infants and children. Although no differential dosing is specified, cautious consideration should be applied to dose selection for geriatric patients. Usage is restricted strictly to external application only, underscoring that the product is never to be used for any disorder other than the condition for which it was prescribed. The administration protocol does not specify a maximum duration, reflecting its typical use for the ongoing management of chronic skin issues.

Research Evidence / Overview of Studies for Lac-Hydrin

---

Evidence for Use in Xerosis (Severe Dry Skin)

Research involving the topical formulation was conducted using short-term Randomized Controlled Trials (RCTs) and controlled comparative studies, including comparisons to non-active vehicles. These study designs were used in research exploring how symptoms change over time in the observed populations. The measured outcomes included patient-reported outcomes describing perceived discomfort, such as itching, alongside instrumental measures that monitored skin surface characteristics like roughness, scaling, and hydration status (capacitance).

Studies report how symptoms evolved in the observed populations over the defined treatment intervals, which were mostly short-term, typically lasting two to four weeks. Findings describe patterns observed in the studies related to changes in clinical severity scores for skin dryness and scaling. However, long-term effects are not fully established, as the primary studies focused on fixed, short treatment periods.

---

Evidence for Use in Ichthyosis Vulgaris (Scaling Disorder)

Research exploring the use of the formulation for ichthyosis vulgaris was conducted using Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Multi-Center Studies. The research explored short-term symptom changes over a defined time interval, usually 28 days. During these periods, researchers monitored outcomes related to symptom intensity or variability, using standardized tools such as the Overall Disease Severity Scale and clinical grading of scaling.

Studies data show patterns related to changes in overall disease severity scores and scaling when the formulation was compared to the non-active vehicle. The research contributes to the broader evidence landscape by providing context on how these severity measures changed within the specific conditions under which the studies were conducted. Comparative evidence is lacking against the full range of non-vehicle alternative treatments studied for ichthyosis.

---

Long-Term Studies and Follow-Up Data

Most of the available evidence is derived from studies with limited follow-up durations. Because the primary trials were short-term, the long-term effects are not fully established, and certainty remains low regarding the condition’s status after the treatment period concludes. There is limited information for long-term outcomes that would require observation over many months or years.

Evidence in Special Populations

The research has studies explored the use of the formulation in certain subgroups, and some trials included older adults with xerosis. However, the official clinical record states that the original trials did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects, meaning that subgroup findings are uncertain for this population. Regarding pregnancy, the current record states that human data on the use of the product during pregnancy remains limited.

Common questions about Lac-Hydrin (FAQ)

---

Q: Does Lac-Hydrin help with rough patches or 'chicken skin' (keratosis pilaris)?

A: The official documentation for Lac-Hydrin indicates its use for the treatment of certain chronic skin conditions characterized by dryness and scaling. Regulatory documents specifically state the medication is indicated for dry, scaly skin (xerosis) and ichthyosis vulgaris.

---

Q: Is it possible to develop an allergy to Lac-Hydrin?

A: Official documents define a history of hypersensitivity (a type of allergic reaction) to any of the product's ingredients as a contraindication for use. If signs of a hypersensitivity reaction are observed while using the medication, regulatory guidance states that the drug is typically discontinued.

---

Q: Can I use other lotions or creams on top of Lac-Hydrin?

A: Regulatory documentation regarding topical products advises caution or avoidance when simultaneously using other topical preparations that are known to cause local effects like skin irritation, peeling, or dryness. This restriction is noted to prevent the exacerbation of local adverse skin reactions due to a potential additive effect.

---

Q: Is the sensation of itching or redness listed as a common or uncommon side effect?

A: According to official adverse reaction data, reactions like erythema (redness) are observed in >10% of patients in studies. Pruritus (itching) is also noted in 1-10% of patients. These are considered frequently observed adverse reactions that are typically confined to the application site and are often temporary.

---

Q: Why is Lac-Hydrin sometimes called a 'chemical exfoliant'?

A: The active ingredient in Lac-Hydrin is classified by regulators as an Alpha-Hydroxy Acid (AHA) derivative. The official mechanism of action involves influencing the structure of the outer skin layer by decreasing corneocyte cohesion, which is a process that facilitates the separation of redundant cellular material.

---

Q: What official studies support the use of Lac-Hydrin for its main indication?

A: The evidence base used to support the approved indications is detailed in official regulatory documents. This includes placebo-controlled, double-blind, randomized, multi-center studies that examined changes in skin symptoms over defined short-term treatment intervals.

---

Q: Does Lac-Hydrin help with scaling or flaking of the skin?

A: Yes, official documents indicate the medication is used for the treatment of conditions that involve scaly skin (xerosis). Additionally, peeling (desquamation) is listed in the adverse reactions section. The mechanism is associated with its effect on the outer layer of the skin.

---

Q: Does Lac-Hydrin have a distinctive smell?

A: The official list of inactive ingredients for the lotion formulation includes the component fragrance. This indicates that a scent is added to the product.

---

Q: How quickly does Lac-Hydrin typically start working for dry skin?

A: Official regulatory documents indicate that the clinical studies supporting the drug's use explored how skin symptoms changed over short-term treatment intervals. These intervals were typically defined as lasting two to four weeks.

---

Q: Can Lac-Hydrin be used on sensitive areas of the body?

A: Official warnings strongly advise against contact with highly sensitive areas, such as the eyes, lips, or mucous membranes. Furthermore, regulatory documents describe a need for caution when the product is used on the face due to the potential for local irritation.

---

Q: Can using too much Lac-Hydrin cause more side effects?

A: Official patient information indicates that the medication is intended for use as directed by the physician. If the underlying skin condition worsens with treatment, official guidance states that the drug is typically discontinued.

---

Q: What happens if a dose of Lac-Hydrin is missed?

A: Consumer guidance derived from official labeling notes that if a scheduled dose is missed, it is generally skipped. The recommendation is to proceed with the next scheduled dose at the regular time, and the dose should not be doubled to make up for the missed one.

---

Q: How long after starting the medication can results be generally expected?

A: Clinical studies supporting the drug's official indications primarily measured outcomes and symptom changes over short-term treatment intervals. These periods were typically defined as lasting between two to four weeks.

---

Q: Is Lac-Hydrin safe for use on the face?

A: Regulatory documents describe a need for caution when the product is used on the face due to the potential for irritation. Due to the risk of sun sensitivity, official patient information also advises individuals to minimize or avoid use of the product on sun-exposed areas, including the face.

---

Q: Why might a patient be instructed to use this medication only on certain days?

A: While the standard labeled regimen involves applying the formulation twice daily, the medication is documented to be used as directed by the physician. Any deviation from the standard schedule would be based on individual clinical guidance.

---

Q: What does the full list of inactive ingredients include?

A: The inactive ingredients listed in the official DailyMed labeling for the lotion/cream may include substances such as cetyl alcohol, fragrance, glycerin, light mineral oil, methyl and propyl parabens, and water, among others.

---

Q: Is Lac-Hydrin gluten-free or paraben-free?

A: The official labeling for both the cream and lotion formulations explicitly lists methyl and propyl parabens among the inactive ingredients. Information regarding the status of ingredients as gluten-free is not documented in the official regulatory labeling.

---

Q: Why is the active ingredient in Lac-Hydrin called 'lactic acid'?

A: The active ingredient is ammonium lactate. Official descriptions state that this compound is chemically a salt formed by neutralizing lactic acid with ammonium hydroxide. This explains the relationship between the final ingredient and lactic acid.

---

Q: Is it recommended to avoid any specific types of clothing while using this product?

A: Official patient information notes that if sun exposure to the applied area is unavoidable, clothing is often worn to protect the skin. This guidance is related to the potential for the product to increase sun sensitivity.

---

Q: Are there documented cases of serious side effects in regulatory reports?

A: The official prescribing text states explicitly that no reactions are explicitly labeled as 'Serious Adverse Reactions'. However, less frequently reported reactions from post-marketing surveillance have included systemic-type reactions such as urticaria (hives) and ecchymoses (bruising).

How to Store and Dispose of Lac-Hydrin

The storage of Lac-Hydrin (ammonium lactate lotion/cream) must adhere strictly to regulated conditions to maintain product stability and ensure household safety.

Official Storage Requirements

Condition	Regulatory Requirement
Temperature Range	Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F).
Environmental Protection	Protect the product from freezing, excess heat, and moisture.
Container Rule	Keep the medication in its original container and ensure it is tightly closed.

Disposal and Safety

This medication must be kept out of the reach and sight of children. For disposal, unused or expired product must be properly discarded and should not be flushed down the toilet or poured into a drain; patients are directed toward drug take-back programs or pharmacist consultation for guidance.